Glucocorticoid treatment for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.
- Author:
Jian-hua LIN
1
;
Zhong-lin CUI
;
Jie ZHOU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Cholestasis, Intrahepatic; complications; Female; Humans; Hydrocortisone; analogs & derivatives; therapeutic use; Hyperbilirubinemia; drug therapy; etiology; Liver Transplantation; Male; Middle Aged; Postoperative Complications; drug therapy
- From: Journal of Southern Medical University 2010;30(2):377-378
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic effect of glucocorticoid on early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.
METHODSThirteen liver transplantation recipients with serum total bilirubin above 171 micromol/L at two weeks to one month postoperatively were enrolled in this study. After exclusion of liver blood supply anomalies, bile duct complications, and acute rejection and establishment of a pathological diagnosis of cholangiole cholestasis by hepatic biopsy, hydrocortisone sodium succinate was infused. The liver functions of the patients were tested at 1 day before and 1 day and 1 week after the treatment. Hepatic biopsy was performed before and 1 week after the treatment to observe histopathological changes.
RESULTSThe serum levels of total bilirubin decreased significantly after the treatment with glucocorticoid. Pathology of the hepatic biopsy demonstrated the resolution of cholangiole cholestasis 1 week after the treatment.
CONCLUSIONGlucocorticoid treatment is effective for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.
